# Scribe Therapeutics Inc. (SCTX) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $28.67, market value $543 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Scribe Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 10.6×**. Each dollar of revenue is priced at 10.6×, a level that requires very high margins or very fast growth to justify.
- **Free-cash-flow yield: -8.6%**. Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -50.9%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -42.6%**. The company reported a net loss over the last twelve months.
- **Return on equity: 15.2%**. 15.2% on shareholders' equity is solid.
- **Return on invested capital: 15.1%**. Return on all capital, debt included, is 15.1%: comfortably above what that capital costs.
- **Return on assets: -27.9%**. Each dollar of assets produces -27.9% of profit.

## Growth
- **Revenue growth (1 yr): 86.7%**. Revenue grew 86.7% over the last year.

## Financial health
- **Net debt / EBITDA: 0.9×**. It would take 0.9 years of operating earnings to repay net borrowings, within the comfortable range.
- **Interest coverage: -10.9×**. Operating profit covers interest only -10.9×: fragile.
- **Current ratio: 0.97** (quick 0.97). Current liabilities exceed current assets, so the company depends on ongoing cash generation or refinancing to pay the next year's bills.
- **Altman Z-score: -1.58**. A Z-score of -1.58 is in the distress zone, a signal to examine the balance sheet closely.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Scribe Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (4 analysts). 4 analysts cover Scribe Therapeutics Inc.; the consensus is strong_buy, with an average price target of $57.00 (+99% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **From 52-week high: -27.6%** (65.6% above the low). Trading 28% below its 52-week high.
- **RSI (14-day): 53**. An RSI of 53 is neutral.

Live score and charts: https://foliofundamentals.com/analyzer?s=SCTX · Page: https://foliofundamentals.com/stocks/sctx

Not investment advice.